Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

ABSTRACT: This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).

DISEASE(S): Neoplasms, Germ Cell And Embryonal,Ovarian Germ Cell Tumor,Ovarian Carcinoma

PROVIDER: 2132825 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)

Project description:This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for prostate cancer.

| 2002219 | ecrin-mdr-crc

Screening for Lung Cancer in Older Patients (PLCO Screening Trial)

| 2132823 | ecrin-mdr-crc

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

| 2132824 | ecrin-mdr-crc

The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)

Project description:<p>The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute (NCI) to determine the effects of screening on cancer-related mortality and secondary endpoints in over 150,000 men and women aged 55 to 74. The screening component of the trial was completed in 2006. However, participants have been under follow-up for cancer incidence and mortality since that time. In addition, PLCO included a large biological sample biorepository which has served as a unique resource for cancer research, particularly for etiologic and early-marker studies. As part of these efforts, PLCO has been used for a large number of genome-wide association and exome sequencing studies for different types of cancer.</p>

| phs001286 | dbGaP

Homo sapiens

Project description:Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)

| PRJNA316639 | ENA

The Prostate, Lung, Colon, Ovary Screening Trial (PLCO): Etiologic and Early Marker Study

Project description:The Prostate, Lung, Colon, Ovary Screening Trial (PLCO): Etiologic and Early Marker Study

| PRJNA371285 | ENA

CGEMS Prostate Cancer GWAS - Stage 1 - PLCO

Project description:<p>The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer genome-wide association study (GWAS) included genotyping approximately 550,000 SNPs (Phase 1A with HumanHap300 and Phase 1B HumanHap240, both from Illumina, San Diego, CA) in 1,172 prostate cancer patients and 1,157 controls of European ancestry from the Prostate, Lung, Colon and Ovarian (PLCO, <a href="http://www.cancer.gov/prevention/plco/" target="_blank">http://www.cancer.gov/prevention/plco/</a>) Cancer Screening Trial. The original analysis published in Nature Genetics [PMID: <a href="http://ncbi.nlm.nih.gov/pubmed/17401363" target="_blank">17401363</a>] included 2,282 subjects. After improvement and revisions of the original analysis, 2,252 subjects were submitted to dbGaP.</p>

| phs000207 | dbGaP

Cancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer Genome-Wide Association Study (GWAS) - Primary Scan (Stage 1) - PLCO Screening Trial

| phs000207.v1.p1 | EGA

Circulating microRNA screening of high-risk individuals enrolled in COSMOS lung cancer screening trial.

Project description:Lung cancer is the leading cause of cancer death worldwide. Low-dose computed tomography screening (LDCT) was recently shown to anticipate the time of diagnosis, thus reducing lung cancer mortality. We identifed a serum microRNA signature (the miR-Test) that could identify the optimal target population for LDCT screening. Here, we performed a large-scale validation study of the miR-Test in high-risk individuals enrolled in the Continuous Observation of Smoking Subjects (COSMOS) lung cancer screening program. RT-qPCR of circulating microRNA purified from serum samples. Trizol-LS and miRNEASY Mini kit (Qiagen) were used for miRNA purification. Custom TaqManÂ® Low Density Array microRNA Custom Panel (Life Technologies) was used to screen serum circulating microRNA.

2016-02-29 | E-GEOD-76462 | biostudies-arrayexpress

Circulating microRNA screening of high-risk individuals enrolled in COSMOS lung cancer screening trial.

2016-02-29 | GSE76462 | GEO